Patient report outcomes: Financial toxicity in cholangiocarcinoma.

• DOI: 10.1200/jco.2022.40.4_suppl.394
• Publication Date: 2022-01-19T20:44:02Z
• Authors: Jessica M. Keilson; Stacie Lindsey; Melinda Bachini; Caroline Medin; Alexandra Berk; Sophia Cornew; Shishir K. Maithel
• Keywords: Intrahepatic Cholangiocarcinoma

394 Background: While surgery is the only curative option for cholangiocarcinoma (CCA), it amenable in a minority of patients and has high recurrence rates. Numerous experimental targeted therapies are under investigation; however, objective health-related quality life (HRQoL) data receiving these currently not available. Methods: Pts engaged Cholangiocarcinoma Foundation completed two validated HRQoL surveys: Functional Assessment Cancer Therapy (FACT)-Hepatobiliary COmprehensive Score financial Toxicity (COST). Subscales (Physical Well-Being, PWB; Social SWB; Emotional EWB; FWB; Hepatobiliary Subscale, HCS; Financial Scale, FTS) composite scores (FACT-Hep, PWB, SWB, EWB, FWB, HCS) were calculated according to FACIT-Manual, with higher values indicating improved HRQoL. Results: 208pts surveys. 75% (n = 156) had intrahepatic CCA, 57% 119) underwent resection, which 48% 56) disease recurrence. 22% 45) enrolled clinical trial 80% 167) molecular profiling, 29% 48) received therapy. pts reported similar compared those trial, they also lower FTS (effect size 0.33, p 0.05), suggesting burden. who therapy equivalent did 0.43, 0.01). Conclusions: Our suggest that enrollment does affect patient’s physical, emotional, social, or functional well-being. However, despite treatments being paid through enrollment, still report This seen among For trials personalized mainly offered late advanced setting, at point significant toll already been endured. Further, often available large academic centers, creating physical barrier access. These findings underscore need increase availability eliminate barriers threaten access utilization progressive therapies.[Table: see text]